HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...

China’s biotech sector may still be developing, but the COVID-19 crisis has revealed just how swiftly it can bring new vaccines to the clinic. The country has more COVID-19 vaccine candidates in human testing than...

Less than one week after entering the clinic, Sinovac became the first company to report animal data supporting its COVID-19 vaccine candidate. Sinovac Biotech Ltd. (NASDAQ:SVA) has PiCoVacc in a Phase I/II study and expects...

With enrollment complete in the Phase I trial of Moderna’s COVID-19 vaccine, BARDA could spend as much as a half-billion dollars to bring mRNA-1273 across the finish line. The news came amid multiple updates for...

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...

Dynavax Technologies Corp. (NASDAQ:DVAX) named Ryan Spencer as CEO and David Novack president and COO. Spencer succeeds Edward Gray, who retired in August. Both Spencer and Novack had been interim co-presidents since May, when the...

Johnson & Johnson (NYSE:JNJ) hired Jim Swanson as EVP and group chief information officer. He was CIO and head of digital transformation, crop science, at Bayer AG (Xetra:BAYN). Swanson replaces Stuart McGuigan, who left in...

Ironwood, Clovis price note deals  Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including $175 million in 0.75% notes maturing in June 2024 and $175 million in 1.5% notes maturing June...

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...